Global Giant Cell Arteritis Drugs Market - 2024-2031

Overview

The global giant cell arteritis drugs market reached US$ 933.2 million in 2023 and is expected to reach US$ 1859.5 million by 2031 growing with a CAGR of 9% during the forecast period 2024-2031.

Giant Cell Arteritis (GCA) or temporal arteritis is a form of vasculitis a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues.

It frequently affects the aorta and its large branches to the head, arms, and legs. GCA is the most common form of vasculitis in adults over the age of 50, most commonly between the ages of 70 and 80 years. Women have the highest risk of developing this disease, which can cause headaches, jaw pain, and changes in or loss of vision, including sudden and permanent loss of vision.

GCA is typically treated with high doses of glucocorticoids such as prednisone, and sometimes with other medications that also suppress the immune system, to control inflammation, biologic drugs, and others.

Market Dynamics: Drivers

The growing geriatric population and the rise in the prevalence of cardiovascular disorders

The demand for the global giant cell arteritis drugs market is driven by multiple factors. One of the key factors is the growing geriatric population and the rise in the prevalence of cardiovascular disorders are contributing to the growth of the GCA treatment market.

As per WHO data in October 2022, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion).

According to the CDC in May 2024, heart disease is the leading cause of death among men, women, and people of racial and ethnic groups in the U.S. One person dies every 37 seconds in the country from cardiovascular disease.

Moreover, GCA is closely linked to cardiovascular disorders. The inflammation caused by GCA can lead to complications such as aortic aneurysms and dissections. As the prevalence of cardiovascular disorders rises, particularly in the aging population, the demand for effective GCA drugs increases to manage these complications and improve patient outcomes.

In addition, rising the number of clinical trials and key players' strategies such as partnerships & collaborations would drive this market growth. According to ClinicalTrials.gov in June 2024, a phase III study of the efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA).

Also, in February 2022, Kiniksa Pharmaceuticals, Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., announced a strategic collaboration to develop and commercialize Kiniksa's ARCALYST and mavrilimumab in the Asia Pacific Region. Phase 2 clinical trials of mavrilimumab in rheumatoid arthritis and giant cell arteritis achieved their primary and secondary endpoints with statistical significance.

Restraints

Factors such as the high cost of treatment, limited availability of approved drugs, lack of awareness & diagnosis among individuals, and adverse effects of treatment, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global giant cell arteritis drugs market is segmented based on drug class, route of administration, distribution channel, and region.

The corticosteroids segment accounted for approximately 65.3% of the global giant cell arteritis drugs market share

The corticosteroids segment is expected to hold the largest market share over the forecast period. Owing to these are the most effective and well-tolerated drugs used to manage giant cell arteritis. Corticosteroids are known to reduce inflammation in the walls of arteries affected by giant cell arteritis, as well as suppressing the immune system which can help reduce the symptoms and prevent permanent damage to the arteries.

According to an Ophthalmology research publication in November 2022, corticosteroids (e.g. prednisone, prednisolone, methylprednisolone) have remained the mainstay of treatment for GCA for the past 70 years due to their profound immunosuppressive effects.

Moreover, key players in the industry more focus on the treatment for GCA, rising number of clinical trials and product approvals would drive this segment growth. For instance, in June 2024, HCPLive discussed a phase 3, randomized, placebo-controlled trial that compared 2 doses of upadacitinib versus placebo among a cohort of patients with giant cell arteritis (GCA). The findings, presented at the 2024 European Congress of Rheumatology (EULAR) conference, focused on the first 52-week study period.

Also, in September 2023, Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.

Geographical Analysis

North America accounted for approximately 43.2% of the global giant cell arteritis drugs market share

North America region is expected to hold the largest market share over the forecast period. The rising prevalence of GCA and well-advanced healthcare infrastructure help to drive this market growth.

As per Springer Open research publication in January 2024, the annual incidence of GCA is approximately 15-25 cases per 100,000 persons and nearly exclusively occurs in people over 50 years old. Whilst the incidence of GCA increases with age, it is twice as common in women as men. The lifetime risk of GCA in women is 1% compared to 0.5% in men.

Moreover, government favorable reimbursement policies, increasing R&D investments, and major players in the industry more focus on clinical trials and product launches & approvals would drive this market growth in this region.

For instance, in May 2023, AbbVie announced the results of Phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg) alone and in combination [ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg)] in adults with moderately to severely active systemic lupus erythematosus (SLE) who continued to receive standard lupus therapies. The study results are being presented as an oral presentation during the European Congress of Rheumatology, EULAR 2023. Upadacitinib (RINVOQ) is in Phase 3 development for giant cell arteritis, Takayasu arteritis, and systemic lupus erythematosus

Also, in April 2024, Fresenius Kabi announced the immediate U.S. availability of Tyenne (tocilizumab-aazg), a biosimilar of Actemra (tocilizumab). Biologic medicine is indicated for the treatment of several autoimmune diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Market Segmentation

By Drug Class

• Corticosteroids
• Immune-suppressing Agents
• Anti Coagulants
• Biologics
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the giant cell arteritis drugs market include Genentech, Inc., F. Hoffmann-La Roche Ltd, Biogen, Novartis AG, Aark Pharmaceuticals, Aetna Inc., Sartorius AG, Fresenius Kabi USA, Bio-Rad Laboratories, Inc and CELLTRION INC among others.

Key Developments

• In April 2024, AbbVie announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA)
• In March 2023, EULAR, Tocilizumab was recommended for new, relapsing giant cell arteritis. Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

Why Purchase the Report?

• To visualize the global giant cell arteritis drugs market segmentation based on drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of giant cell arteritis drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global giant cell arteritis drugs market report would provide approximately 62 tables, 55 figures, and 183 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies